



Jim Doyle  
Governor

Helene Nelson  
Secretary

State of Wisconsin

Department of Health and Family Services

Telephone: 608-266-8922

FAX: 608-266-1096

TTY: 608-261-7798

dhfs.wisconsin.gov

**OPEN MEETING NOTICE  
MEDICAID PHARMACY  
PRIOR AUTHORIZATION ADVISORY COMMITTEE**

**Wednesday, June 8, 2005  
8:30 a.m. – 4:30 p.m.  
Wisconsin State Office Building  
1 W. Wilson Street, Room 751  
Madison, Wisconsin 53701**

**AGENDA**

- |                         |  |                                   |
|-------------------------|--|-----------------------------------|
| 8:30 a.m. – 8:45 a.m.   | <b>I. Opening</b>  | Mark Moody, Administrator         |
|                         | <b>Remarks/Introductions</b>   | Division of Health Care Financing |
| 8:45 a.m. – 10:15 a.m.  | <b>II. Public Comment</b>  |                                   |
| 10:15 a.m. – 10:30 a.m. | <b>III. Break</b>  |                                   |
| 10:30 a.m. – 12:00 p.m. | <b>IV. Public Comment cont.</b>  |                                   |
| 12:00 p.m. – 12:15 p.m. | <b>V. Break/Lunch</b>  |                                   |
| 12:15 a.m. – 2:15 p.m.  | <b>VI. Discussion of<br/>Manufacturer-Specific<br/>Supplemental Rebate<br/>Amounts (Closed<br/>Session)*</b>         |                                   |
| 2:15 p.m. – 2:30 p.m.   | <b>VII. Break</b>  |                                   |
| 2:30 p.m. – 4:30 p.m.   | <b>VIII. Therapeutic Class<br/>Reviews, Committee<br/>Discussion and<br/>Response to Proposal<br/>(Open Session)</b> |                                   |

- Drug Classes for Review:**
- Alzheimer’s Agents (Alzheimer’s Disease)
  - Antiparkinson’s Agents (Parkinson’s Disease)
  - Stimulants and Related Agents (Attention deficit disorder and attention deficit hyperactivity disorder )
  - Sedative Hypnotics (Insomnia and sleep disorders)
  - Anticoagulants, Injectables (Clot prevention)
  - Hepatitis C Agents (Viral infection of the liver)
  - Cytokine and CAM Antagonists (Rheumatoid arthritis and psoriasis)
  - Growth Hormone (Growth deficiencies in children)
  - Erythropoiesis Stimulating Proteins (Treatment of low blood levels)

\* Intended for consideration in closed session pursuant to s. 19.85(1)(e), Wis. Stats.

**Contact Person:** Rita Hallett (608) 267-0938, Email - [haller@dhfs.state.wi.us](mailto:haller@dhfs.state.wi.us)

**Accessibility:** The meeting is accessible for people with mobility impairments. Handicapped parking is available in the back of the building in the parking lot. Accessible entrance is found in back of the building nearest the handicapped parking or in front of the building, using the side entrance. People needing special accommodations to attend or participate in the meeting should notify the contact person at least five working days prior to the meeting.

cc: State Editor, Milwaukee Journal Sentinel  
State Editor, The Capital Times  
State Editor, Wisconsin State Journal

Posted - State Capitol Building  
Posted - 1 W. Wilson St., Madison

## Medicaid Prior Authorization Advisory Committee Meeting

### Public Testimony Guidelines:

1. Speakers will be required to sign up with the Division of Health Care Financing (DHCF) prior to the meeting. Speakers will be selected on a first come first serve basis. Please contact Rita Hallett at (608) 267-0938 or via email at [haller@dhfs.state.wi.us](mailto:haller@dhfs.state.wi.us) to reserve a time slot.
2. Speakers must submit a written copy of their testimony either prior to or at the meeting. Testimony copies may be submitted via email to Rita Hallett or mailed to the DHCF.
3. A maximum of 36 speakers will be permitted. Should all slots for spoken testimony become filled, parties are invited to submit written testimony for review and consideration by the committee. Written testimony should be submitted to Rita Hallett via email at [haller@dhfs.state.wi.us](mailto:haller@dhfs.state.wi.us) or mailed to the Division of Health Care Financing, Attn: Rita Hallett, 1 W. Wilson Street, Room 350, Madison, WI 53702.
4. Only one speaker per company or organization will be permitted.
5. Speakers will be required to state name, address, organization represented and the drug name and class applicable to their testimony.
6. Speakers will be limited to a period of 5 minutes.
7. Speakers will not be permitted to use audio/visual equipment during their presentation.
8. Prior Authorization Committee members will not ask questions or respond to speakers at the meeting.